Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release morphine for refractory breathlessness in opioid-naive adults with primary pulmonary hypertension
ACTRN12609000209291Phase 3Recruiting
- Sponsor
- Flinders University
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of morphine hydrochloride in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Flinders University. Primary endpoint: Relief of breathlessness by Dyspnoea Visual Analogue Scale. Started Apr 2009; status: recruiting.
02
Drugs
morphine hydrochloride
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12609000209291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000209291.